Boston biotech Entrada launches with $59M to tackle deadly disease

Entrada Therapeutics is launching with a $59M VC round, using science developed by Ohio State University professor and company co-founder Dehua Pei to deliver treatment to previously un-druggable targets in a cell's mitochondrion.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.